The gap between trailing and forward P/E suggests investors are capitalizing a recovery in earnings from the depressed 2025 base rather than the current run-rate. Compared with CHRW at 26.6x trailing and HUBG at 14.8x, LSTR's trailing multiple appears elevated, though this is partly an artifact of depressed prior-year earnings. Investors should monitor whether forward estimates hold, since a reversal in spot-market tightness would leave the current premium difficult to justify on the reported margin base.

The 2026Q1 gross margin spike to 22.6% reversed to 13.4% within two quarters, suggesting that the peak reflected transient spot-rate conditions rather than a structural shift in the take rate. Operating margin of 4.2% against a 13.4% gross margin means roughly two-thirds of gross profit is consumed before operating income, which constrains operating leverage. Net margin of 3.2% sits well below CHRW's 3.6% only marginally, but CHRW's 39.6% ROE reflects a far more capital-efficient structure than LSTR's.

The return recovery appears driven primarily by margin improvement, as asset turnover has held steady near 0.7x to 0.9x, meaning capital intensity has not materially changed. ROE of 5.8% in 2026Q3 is modest relative to CHRW's 39.6%, reflecting LSTR's lower leverage and conservative capital structure rather than weak operations. The trajectory suggests returns are cyclically recovering, and sustainability depends on whether gross margins hold above the 13% floor.

The move from near-zero leverage to a modest D/E of 0.18 is directionally notable, though debt levels remain small relative to the company's cash position of roughly $297M. Interest coverage at elevated levels indicates the incremental borrowing poses no near-term service strain on reported earnings. Investors should monitor the pace of further debt accumulation, since the balance sheet's historical fortress characteristics were a meaningful part of the equity thesis.